奥希替尼片Osimertinib 80mg

Adjuvant treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, following tumor resection. Treatment for adult patients with metastatic NSCLC harboring EGFR T790M mutations.

Recommended Dose: 80 mg orally once daily.

Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for relevant symptoms and manage promptly if they occur. QTc Interval Prolongation, Cardiomyopathy, Keratitis, Cutaneous Vasculitis: Conduct regular monitoring for these conditions during treatment. Erythema Multiforme and Stevens-Johnson Syndrome: Be alert to the occurrence of these severe skin reactions and take appropriate intervention measures. Embryo-Fetal Toxicity: May cause fetal harm; effective contraceptive measures should be taken during treatment.

Leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, neutropenia, xeroderma, fatigue, and cough.

30 tablets per bottle.

Store in a cool, dry place (not exceeding 30℃) and protected from light. Keep out of the reach of children.